Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 40 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ropivacaine hydrochloride monohydrate, quantity: 52.9 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine actavis for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ropivacaine hydrochloride monohydrate, quantity: 105.8 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine actavis for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium ascorbate, quantity: 113 mg (equivalent: ascorbic acid, qty 100 mg); folic acid, quantity: 0.4 mg; pyridoxine hydrochloride, quantity: 4.9 mg (equivalent: pyridoxine, qty 4 mg); nicotinamide, quantity: 40 mg; cyanocobalamin, quantity: 5 microgram; thiamine nitrate, quantity: 3.1 mg; biotin, quantity: 60 microgram; sodium pantothenate, quantity: 16.5 mg (equivalent: pantothenic acid, qty 15 mg); riboflavine sodium phosphate, quantity: 4.9 mg (equivalent: riboflavine, qty 3.6 mg) - injection, powder for - excipient ingredients: edetate sodium; methyl hydroxybenzoate; glycine - soluvit n is intended as a supplement in intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in adults, adolescents, children and infants. fat-soluble vitamins should also be administered to patients receiving prolonged parenteral nutrition.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - xylocaine (lidocaine hcl) injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - ropivacaine hydrochloride (unii: v910p86109) (ropivacaine - unii:7io5lya57n) - ropivacaine hydrochloride 5 mg in 1 ml - naropin is indicated for the production of local or regional anesthesia for surgery and for acute pain management. surgical anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration acute pain management: epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration naropin is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible